These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2182064)

  • 1. Safety evaluation of biotechnology products.
    Zbinden G
    Drug Saf; 1990; 5 Suppl 1():58-64. PubMed ID: 2182064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issues with biotechnology products in toxicologic pathology.
    Terrell TG; Green JD
    Toxicol Pathol; 1994; 22(2):187-93. PubMed ID: 7973366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of biological and biotechnology-derived medicines.
    Dayan AD
    Toxicology; 1995 Dec; 105(1):59-68. PubMed ID: 8638284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preclinical evaluation of the safety of biotechnology products: specific aspects].
    Descotes J; Ravel G; Vial T
    Therapie; 2003; 58(2):139-43. PubMed ID: 12942854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of biotechnology products for therapeutic use.
    Sims J
    Toxicol Lett; 2001 Mar; 120(1-3):59-66. PubMed ID: 11323162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotoxicity testing of biotechnology-derived products. Report of a GUM task force. Gesellschaft für Umweltmutationsforschung.
    Gocke E; Albertini S; Brendler-Schwaab S; Müller L; Suter W; Würgler FE
    Mutat Res; 1999 Mar; 436(2):137-56. PubMed ID: 10095137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conclusions of the satellite symposium of the Eurotox '91 Congress on Safety Aspects of Biotechnology-Derived Drugs.
    Hum Exp Toxicol; 1992 Sep; 11(5):369-72. PubMed ID: 1358153
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety assessment of biotechnology-derived pharmaceutical products. General principles and the relevant cases.
    Maki E
    J Toxicol Sci; 1996 Dec; 21(5):531-3. PubMed ID: 9035066
    [No Abstract]   [Full Text] [Related]  

  • 11. Progress and challenges in the preclinical assessment of cytokines.
    Hayes TJ; Cavagnaro JA
    Toxicol Lett; 1992 Dec; 64-65 Spec No():291-7. PubMed ID: 1471184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current guidelines for the preclinical safety assessment of therapeutic proteins.
    Bass R; Kleeberg U; Schröder H; Scheibner E
    Toxicol Lett; 1992 Dec; 64-65 Spec No():339-47. PubMed ID: 1471190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotechnology products intended for human use, toxicological targets and research strategies.
    Zbinden G
    Prog Clin Biol Res; 1987; 235():143-59. PubMed ID: 2440056
    [No Abstract]   [Full Text] [Related]  

  • 14. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
    Koren E; Smith HW; Shores E; Shankar G; Finco-Kent D; Rup B; Barrett YC; Devanarayan V; Gorovits B; Gupta S; Parish T; Quarmby V; Moxness M; Swanson SJ; Taniguchi G; Zuckerman LA; Stebbins CC; Mire-Sluis A
    J Immunol Methods; 2008 Apr; 333(1-2):1-9. PubMed ID: 18275969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difficulties in conceiving and applying guidelines for the safety evaluation of biotechnologically-produced drugs: some examples.
    Claude JR
    Toxicol Lett; 1992 Dec; 64-65 Spec No():349-55. PubMed ID: 1471191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
    Pilling AM
    Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of protein safety in the context of agricultural biotechnology.
    Delaney B; Astwood JD; Cunny H; Conn RE; Herouet-Guicheney C; Macintosh S; Meyer LS; Privalle L; Gao Y; Mattsson J; Levine M;
    Food Chem Toxicol; 2008 May; 46 Suppl 2():S71-97. PubMed ID: 18348900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals.
    Dempster AM
    Biotechnol Annu Rev; 2000; 5():221-58. PubMed ID: 10875002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.